Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia

New England Journal of Medicine - United States
doi 10.1056/nejmoa043800
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Massachusetts Medical Society

Related search

The Use of Anagrelide in Myeloproliferative Neoplasms, With Focus on Essential Thrombocythemia

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

Takotsubo Cardiomyopathy in a Patient With Essential Thrombocythemia Treated With Anagrelide: Case Report

Cor et Vasa
Cardiovascular MedicineCardiology
2018English

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2019English

Prinzmetal Angina in a Young Patient With Essential Thrombocythemia, After Anagrelide Initiation - Case Report and Literature Review

ARS Medica Tomitana
BiochemistryMedicineGeneticsMolecular Biology
2018English

Essential Thrombocythemia

New England Journal of Medicine
Medicine
2020English

Essential Thrombocythemia

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2007English

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled After the FDA Approval Date of Anagrelide

American Journal of Hematology
Hematology
2018English

ASXL1 Mutations in Chinese Patients With Essential Thrombocythemia

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Efficacy and Safety of Anagrelide as a First‐line Drug in Cytoreductive Treatment‐naïve Essential Thrombocythemia Patients in a Real‐world Setting

European Journal of Haematology
MedicineHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy